{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:11:10Z","timestamp":1789575070511,"version":"build-2803163510"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10361-1","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T14:39:46Z","timestamp":1739803186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Integrating alternative therapies in overcoming chemotherapy resistance in tumors"],"prefix":"10.1007","volume":"52","author":[{"given":"Sana S.","family":"Alqarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najeeb Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"10361_CR1","unstructured":"WHO. (2024, February 1). Global cancer burden growing, amidst mounting need for services. Retrieved from https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services"},{"issue":"6","key":"10361_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1470-2045(19)30163-9","volume":"20","author":"BE Wilson","year":"2019","unstructured":"Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB (2019) Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study, The Lancet. Oncology 20(6):769\u2013780. https:\/\/doi.org\/10.1016\/S1470-2045(19)30163-9","journal-title":"Oncology"},{"key":"10361_CR3","doi-asserted-by":"publisher","unstructured":"Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer drug resistance (Alhambra, Calif.), 2(2), 141\u2013160. https:\/\/doi.org\/10.20517\/cdr.2019.10","DOI":"10.20517\/cdr.2019.10"},{"key":"10361_CR4","doi-asserted-by":"crossref","unstructured":"Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., ... & de la Lastra, J. M. P. (2023). Cancer chemotherapy and beyond Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 10(4): 1367\u20131401.","DOI":"10.1016\/j.gendis.2022.02.007"},{"issue":"14","key":"10361_CR5","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/cells13141186","volume":"13","author":"MA Rahman","year":"2024","unstructured":"Rahman MA, Rakib-Uz-Zaman SM, Chakraborti S, Bhajan SK, Gupta RD, Jalouli M, Parvez MAK, Shaikh MH, Hoque Apu E, Harrath AH et al (2024) Advancements in utilizing natural compounds for modulating autophagy in liver cancer: molecular mechanisms and therapeutic targets. Cells 13(14):1186. https:\/\/doi.org\/10.3390\/cells13141186","journal-title":"Cells"},{"issue":"1","key":"10361_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/biomedicines12010201","volume":"12","author":"P Chunarkar-Patil","year":"2024","unstructured":"Chunarkar-Patil P, Kaleem M, Mishra R, Ray S, Ahmad A, Verma D, Bhayye S, Dubey R, Singh HN, Kumar S (2024) Anticancer drug discovery based on natural products: from computational approaches to clinical studies. Biomedicines 12(1):201. https:\/\/doi.org\/10.3390\/biomedicines12010201","journal-title":"Biomedicines"},{"issue":"10","key":"10361_CR7","doi-asserted-by":"publisher","first-page":"11149","DOI":"10.1002\/cam4.5698","volume":"12","author":"Q Wang","year":"2023","unstructured":"Wang Q, Shao X, Zhang Y, Zhu M, Wang FXC, Mu J, Li J, Yao H, Chen K (2023) Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Med 12(10):11149\u201311165. https:\/\/doi.org\/10.1002\/cam4.5698","journal-title":"Cancer Med"},{"issue":"17","key":"10361_CR8","doi-asserted-by":"publisher","first-page":"9451","DOI":"10.3390\/ijms22179451","volume":"22","author":"A Ramos","year":"2021","unstructured":"Ramos A, Sadeghi S, Tabatabaeian H (2021) Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci 22(17):9451. https:\/\/doi.org\/10.3390\/ijms22179451","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10361_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.0306-5251.2001.01548.x","volume":"53","author":"L Bertilsson","year":"2002","unstructured":"Bertilsson L, Dahl ML, Dal\u00e9n P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53(2):111\u2013122. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01548.x","journal-title":"Br J Clin Pharmacol"},{"key":"10361_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105934","volume":"174","author":"YX Chen","year":"2021","unstructured":"Chen YX, Wang CJ, Xiao DS, He BM, Li M, Yi XP, Liu ZQ (2021) eIF3a R803K mutation mediates chemotherapy resistance by inducing cellular senescence in small cell lung cancer. Pharmacol Res 174:105934","journal-title":"Pharmacol Res"},{"key":"10361_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.11.005","volume":"24","author":"NG Alkema","year":"2016","unstructured":"Alkema NG, Wisman GBA, van der Zee AG, van Vugt MA, de Jong S (2016) Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updates 24:55\u201369","journal-title":"Drug Resist Updates"},{"issue":"9","key":"10361_CR12","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R (2020) Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 21(9):3233. https:\/\/doi.org\/10.3390\/ijms21093233","journal-title":"Int J Mol Sci"},{"key":"10361_CR13","doi-asserted-by":"publisher","unstructured":"Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017). The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 8(5): 8921\u20138946. https:\/\/doi.org\/10.18632\/oncotarget.13475","DOI":"10.18632\/oncotarget.13475"},{"issue":"5","key":"10361_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2174\/138161282005140214165212","volume":"20","author":"YH Choi","year":"2014","unstructured":"Choi YH, Yu AM (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20(5):793\u2013807. https:\/\/doi.org\/10.2174\/138161282005140214165212","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10361_CR15","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.ajpath.2012.02.024","volume":"180","author":"L Bao","year":"2012","unstructured":"Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180(6):2490\u20132503. https:\/\/doi.org\/10.1016\/j.ajpath.2012.02.024","journal-title":"Am J Pathol"},{"issue":"1","key":"10361_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/ol.2014.2692","volume":"9","author":"F Gao","year":"2015","unstructured":"Gao F, Dong W, Yang W, Liu J, Zheng Z, Sun K (2015) Expression of P-gp in acute myeloid leukemia and the reversal function of As2O3 on drug resistance. Oncol Lett 9(1):177\u2013182. https:\/\/doi.org\/10.3892\/ol.2014.2692","journal-title":"Oncol Lett"},{"issue":"9","key":"10361_CR17","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","volume":"288","author":"MD Pizzagalli","year":"2021","unstructured":"Pizzagalli MD, Bensimon A, Superti-Furga G (2021) A guide to plasma membrane solute carrier proteins. FEBS J 288(9):2784\u20132835. https:\/\/doi.org\/10.1111\/febs.15531","journal-title":"FEBS J"},{"key":"10361_CR18","doi-asserted-by":"publisher","first-page":"3028387","DOI":"10.1155\/2020\/3028387","volume":"2020","author":"AM Alzahrani","year":"2020","unstructured":"Alzahrani AM, Rajendran P (2020) The multifarious link between cytochrome P450s and cancer. Oxid Med Cell Longev 2020:3028387. https:\/\/doi.org\/10.1155\/2020\/3028387","journal-title":"Oxid Med Cell Longev"},{"key":"10361_CR19","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/bjc.2014.386","volume":"111","author":"L Sawers","year":"2014","unstructured":"Sawers L, Ferguson M, Ihrig B et al (2014) Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumor cell lines. Br J Cancer 111:1150\u20131158. https:\/\/doi.org\/10.1038\/bjc.2014.386","journal-title":"Br J Cancer"},{"issue":"5","key":"10361_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/antiox10050701","volume":"10","author":"RR Singh","year":"2021","unstructured":"Singh RR, Reindl KM (2021) Glutathione S-transferases in Cancer. Antioxidants (Basel, Switzerland) 10(5):701. https:\/\/doi.org\/10.3390\/antiox10050701","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"9","key":"10361_CR21","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.3390\/cancers13092053","volume":"13","author":"CM Neophytou","year":"2021","unstructured":"Neophytou CM, Panagi M, Stylianopoulos T, Papageorgis P (2021) The Role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities. Cancers 13(9):2053. https:\/\/doi.org\/10.3390\/cancers13092053","journal-title":"Cancers"},{"key":"10361_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","volume":"164","author":"C Wigerup","year":"2016","unstructured":"Wigerup C, P\u00e5hlman S, Bexell D (2016) Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther 164:152\u2013169","journal-title":"Pharmacol Ther"},{"issue":"11","key":"10361_CR23","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.3390\/cancers12113244","volume":"12","author":"R P\u00e9rez-Tom\u00e1s","year":"2020","unstructured":"P\u00e9rez-Tom\u00e1s R, P\u00e9rez-Guill\u00e9n I (2020) Lactate in the tumor microenvironment: an essential molecule in Cancer progression and treatment. Cancers 12(11):3244. https:\/\/doi.org\/10.3390\/cancers12113244","journal-title":"Cancers"},{"issue":"7","key":"10361_CR24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/onc.2017.387","volume":"37","author":"Y Qiao","year":"2018","unstructured":"Qiao Y, Zhang C, Li A, Wang D, Luo Z, Ping Y, Zhang Y (2018) IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. Oncogene 37(7):873\u2013883","journal-title":"Oncogene"},{"issue":"1","key":"10361_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah LN, Chow EK (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2(1):3. https:\/\/doi.org\/10.1186\/2001-1326-2-3","journal-title":"Clin Transl Med"},{"issue":"1","key":"10361_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13148-021-01107-4","volume":"13","author":"S Keyvani-Ghamsari","year":"2021","unstructured":"Keyvani-Ghamsari S, Khorsandi K, Rasul A, Zaman MK (2021) Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin Epigenetics 13(1):120. https:\/\/doi.org\/10.1186\/s13148-021-01107-4","journal-title":"Clin Epigenetics"},{"key":"10361_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00280-015-2861-1","volume":"76","author":"AM Tsimberidou","year":"2015","unstructured":"Tsimberidou AM (2015) Targeted therapy in cancer. Cancer Chemother Pharmacol 76:1113\u20131132","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10361_CR28","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles G, Barrett M, Fo\u00e0 R, Maurer J, O\u2019Brien S, Valente N, Wenger M, Maloney DG (2017) Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34(10):2232\u20132273. https:\/\/doi.org\/10.1007\/s12325-017-0612-x","journal-title":"Adv Ther"},{"issue":"9","key":"10361_CR29","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","volume":"21","author":"JD Hainsworth","year":"2003","unstructured":"Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21(9):1746\u20131751","journal-title":"J Clin Oncol"},{"key":"10361_CR30","doi-asserted-by":"crossref","unstructured":"Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., ... & Perez, E. A. (2013). Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2\u2013positive metastatic breast cancer.\u00a0Journal of Clinical Oncology,\u00a031(9), 1157\u20131163.","DOI":"10.1200\/JCO.2012.44.9694"},{"issue":"2","key":"10361_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discovery 22(2):101\u2013126. https:\/\/doi.org\/10.1038\/s41573-022-00579-0","journal-title":"Nat Rev Drug Discovery"},{"issue":"7","key":"10361_CR32","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","volume":"22","author":"CS Baik","year":"2017","unstructured":"Baik CS, Myall NJ, Wakelee HA (2017) Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. Oncologist 22(7):786\u2013796. https:\/\/doi.org\/10.1634\/theoncologist.2016-0458","journal-title":"Oncologist"},{"issue":"1","key":"10361_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.molonc.2007.01.003","volume":"1","author":"T Ben-Kasus","year":"2007","unstructured":"Ben-Kasus T, Schechter B, Sela M, Yarden Y (2007) Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol 1(1):42\u201354. https:\/\/doi.org\/10.1016\/j.molonc.2007.01.003","journal-title":"Mol Oncol"},{"key":"10361_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13058-015-0648-2","volume":"17","author":"D Mendes","year":"2015","unstructured":"Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, Andrade S, Batel-Marques F (2015) The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer\u2013a systematic review. Breast cancer research\u202f: BCR 17:140. https:\/\/doi.org\/10.1186\/s13058-015-0648-2","journal-title":"Breast cancer research : BCR"},{"key":"10361_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113458","volume":"153","author":"X Wang","year":"2022","unstructured":"Wang X, Zeng X, Li D, Zhu C, Guo X, Feng L, Yu Z (2022) PARP inhibitors in small cell lung cancer: the underlying mechanisms and clinical implications. Biomed Pharmacother 153:113458","journal-title":"Biomed Pharmacother"},{"key":"10361_CR36","doi-asserted-by":"publisher","unstructured":"Wen, M., Xia, J., Sun, Y., Wang, X., Fu, X., Zhang, Y., Zhang, Z., Zhou, Y., & Li, X. (2018). Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation. Biologics: targets & therapy, 12: 183\u2013190. https:\/\/doi.org\/10.2147\/BTT.S169305","DOI":"10.2147\/BTT.S169305"},{"key":"10361_CR37","unstructured":"Lenz H. J. (2007). Cetuximab in the management of colorectal cancer. Biologics: targets & therapy, 1(2), 77\u201391."},{"issue":"2","key":"10361_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G Von Minckwitz","year":"2017","unstructured":"Von Minckwitz G, Procter M, De Azambuja E, Zardavas D, Benyunes M, Viale G, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122\u2013131","journal-title":"N Engl J Med"},{"issue":"10","key":"10361_CR39","doi-asserted-by":"publisher","first-page":"9903","DOI":"10.1007\/s11033-022-07525-8","volume":"49","author":"SL Gupta","year":"2022","unstructured":"Gupta SL, Basu S, Soni V, Jaiswal RK (2022) Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep 49(10):9903\u20139913. https:\/\/doi.org\/10.1007\/s11033-022-07525-8","journal-title":"Mol Biol Rep"},{"issue":"1","key":"10361_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543784.2019.1552255","volume":"28","author":"AS Heimes","year":"2019","unstructured":"Heimes AS, Schmidt M (2019) Atezolizumab for the treatment of triple-negative breast cancer. Expert Opin Investig Drugs 28(1):1\u20135","journal-title":"Expert Opin Investig Drugs"},{"issue":"39","key":"10361_CR41","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.2174\/1381612823666171004120152","volume":"23","author":"Q Geng","year":"2017","unstructured":"Geng Q, Jiao P, Jin P, Su G, Dong J, Yan B (2017) PD-1\/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules. Curr Pharm Des 23(39):6033\u20136041","journal-title":"Curr Pharm Des"},{"key":"10361_CR42","doi-asserted-by":"publisher","first-page":"1044327","DOI":"10.3389\/fonc.2023.1044327","volume":"13","author":"B Yang","year":"2023","unstructured":"Yang B, Wang B, Chen Y, Wan N, Xie F, Yang N, Lu L, Xiao W, Yuan J, Li J, Xie B, Ji B (2023) Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. Front Oncol 13:1044327. https:\/\/doi.org\/10.3389\/fonc.2023.1044327","journal-title":"Front Oncol"},{"issue":"1","key":"10361_CR43","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1186\/s12885-022-10168-4","volume":"22","author":"C Deutschmann","year":"2022","unstructured":"Deutschmann C, Bartsch R, Singer CF, Gschwantler-Kaulich D, Seifert M, Leser C, Marhold M, Bago-Horvath Z, Pfeiler G (2022) Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria. BMC Cancer 22(1):1099. https:\/\/doi.org\/10.1186\/s12885-022-10168-4","journal-title":"BMC Cancer"},{"issue":"1","key":"10361_CR44","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13048-021-00862-5","volume":"14","author":"J Zhu","year":"2021","unstructured":"Zhu J, Yan L, Wang Q (2021) Efficacy of PD-1\/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. Journal of ovarian research 14(1):112. https:\/\/doi.org\/10.1186\/s13048-021-00862-5","journal-title":"Journal of ovarian research"},{"issue":"1","key":"10361_CR45","doi-asserted-by":"publisher","first-page":"e2024010","DOI":"10.4084\/MJHID.2024.010","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa U, Sica S, Pelosi E, Castelli G, Leone G (2024) CAR-T cell therapy in B-cell acute lymphoblastic leukemia. Mediterranean J Hematol Infect Dis 16(1):e2024010. https:\/\/doi.org\/10.4084\/MJHID.2024.010","journal-title":"Mediterranean J Hematol Infect Dis"},{"key":"10361_CR46","doi-asserted-by":"crossref","unstructured":"Guo, Y., Ashrafizadeh, M., Tambuwala, M. M., Ren, J., Orive, G., & Yu, G. (2024). P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators. Drug Discovery Today, 104161.","DOI":"10.1016\/j.drudis.2024.104161"},{"key":"10361_CR47","doi-asserted-by":"publisher","unstructured":"Drake C. G. (2012). Combination immunotherapy approaches.\u00a0Annals of oncology : official journal of the European Society for Medical Oncology,\u00a023 Suppl 8(Suppl 8), viii41\u2013viii46. https:\/\/doi.org\/10.1093\/annonc\/mds262","DOI":"10.1093\/annonc\/mds262"},{"key":"10361_CR48","doi-asserted-by":"crossref","unstructured":"Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., ... & Hwu, P. (2011). gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.\u00a0New England Journal of Medicine. 364(22): 2119\u20132127.","DOI":"10.1056\/NEJMoa1012863"},{"issue":"9","key":"10361_CR49","doi-asserted-by":"publisher","first-page":"e20224","DOI":"10.1016\/j.heliyon.2023.e20224","volume":"9","author":"K Al-Shami","year":"2023","unstructured":"Al-Shami K, Awadi S, Khamees A, Alsheikh AM, Al-Sharif S, Ala\u2019 Bereshy R, Al-Eitan SF, Banikhaled SH, Al-Qudimat AR, Al-Zoubi RM, Al Zoubi MS (2023) Estrogens and the risk of breast cancer: A narrative review of literature. Heliyon 9(9):e20224. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20224","journal-title":"Heliyon"},{"issue":"1","key":"10361_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2011.05.004","volume":"132","author":"HL Claahsen-Van Der Grinten","year":"2011","unstructured":"Claahsen-Van Der Grinten HL, Stikkelbroeck NMML, Otten BJ, Hermus ARMM (2011) Congenital adrenal hyperplasia\u2014pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Ther 132(1):1\u201314","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10361_CR51","first-page":"S3","volume":"9","author":"MA Perlmutter","year":"2007","unstructured":"Perlmutter MA, Lepor H (2007) Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 9(1):S3\u2013S8","journal-title":"Rev Urol"},{"key":"10361_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/BCTT.S196240","volume":"12","author":"M Iorfida","year":"2020","unstructured":"Iorfida M, Mazza M, Munzone E (2020) Fulvestrant in combination with CDK4\/6 inhibitors for HER2- metastatic breast cancers: current perspectives. Breast cancer (Dove Medical Press) 12:45\u201356. https:\/\/doi.org\/10.2147\/BCTT.S196240","journal-title":"Breast cancer (Dove Medical Press)"},{"issue":"1","key":"10361_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-007-9700-y","volume":"105","author":"D Koeberle","year":"2007","unstructured":"Koeberle D, Thuerlimann B (2007) Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1\u201398. Breast Cancer Res Treat 105(1):55\u201366. https:\/\/doi.org\/10.1007\/s10549-007-9700-y","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10361_CR54","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","volume":"19","author":"RJ Auchus","year":"2014","unstructured":"Auchus RJ, Yu MK, Nguyen S, Mundle SD (2014) Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 19(12):1231\u20131240. https:\/\/doi.org\/10.1634\/theoncologist.2014-0167","journal-title":"Oncologist"},{"key":"10361_CR55","unstructured":"Radiation-hormone therapy combination may slow growth of oligometastatic prostate cancer - American Society for Radiation Oncology (ASTRO). ASTRO. Published October 25, 2022. Accessed December 20, 2024. https:\/\/www.astro.org\/news-and-publications\/news-and-media-center\/news-releases\/2022\/radiation-hormone-therapy-combination-may-slow-growth-of-oligometastatic-prostate-cancer"},{"key":"10361_CR56","doi-asserted-by":"crossref","unstructured":"Jen\u010da, A., Mills, D. K., Ghasemi, H., Saberian, E., Jen\u010da, A., Karimi Forood, A. M., ... & Ebrahimifar, M. (2024). Herbal Therapies for Cancer Treatment: A Review of Phytotherapeutic Efficacy. Biologics: Targets and Therapy, 229\u2013255.","DOI":"10.2147\/BTT.S484068"},{"issue":"9","key":"10361_CR57","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/life12091427","volume":"12","author":"SA Gabr","year":"2022","unstructured":"Gabr SA, Elsaed WM, Eladl MA, El-Sherbiny M, Ebrahim HA, Asseri SM, Eltahir YAM, Elsherbiny N, Eldesoqui M (2022) Curcumin modulates oxidative stress, fibrosis, and apoptosis in drug-resistant cancer cell lines. Life (Basel, Switzerland) 12(9):1427. https:\/\/doi.org\/10.3390\/life12091427","journal-title":"Life (Basel, Switzerland)"},{"issue":"5","key":"10361_CR58","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/ph16050755","volume":"16","author":"P Hankittichai","year":"2023","unstructured":"Hankittichai P, Thaklaewphan P, Wikan N, Ruttanapattanakul J, Potikanond S, Smith DR, Nimlamool W (2023) Resveratrol enhances cytotoxic effects of Cisplatin by inducing cell cycle arrest and apoptosis in ovarian adenocarcinoma SKOV-3 cells through activating the p38 MAPK and suppressing AKT. Pharmaceuticals (Basel, Switzerland) 16(5):755. https:\/\/doi.org\/10.3390\/ph16050755","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"3","key":"10361_CR59","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3109\/07357907.2010.550592","volume":"29","author":"ZY He","year":"2011","unstructured":"He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J (2011) Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 29(3):208\u2013213","journal-title":"Cancer Invest"},{"key":"10361_CR60","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3389\/fonc.2019.00749","volume":"9","author":"S Lin","year":"2019","unstructured":"Lin S, An X, Guo Y, Gu J, Xie T, Wu Q, Sui X (2019) Meta-analysis of astragalus-containing traditional chinese medicine combined with chemotherapy for colorectal cancer: efficacy and safety to tumor response. Front Oncol 9:749. https:\/\/doi.org\/10.3389\/fonc.2019.00749","journal-title":"Front Oncol"},{"issue":"21","key":"10361_CR61","doi-asserted-by":"publisher","first-page":"10745","DOI":"10.18632\/oncotarget.2534","volume":"5","author":"L Masuelli","year":"2014","unstructured":"Masuelli L, Di Stefano E, Fantini M et al (2014) Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas. Oncotarget 5(21):10745\u201310762. https:\/\/doi.org\/10.18632\/oncotarget.2534","journal-title":"Oncotarget"},{"issue":"16","key":"10361_CR62","doi-asserted-by":"publisher","first-page":"8405","DOI":"10.3390\/ijms22168405","volume":"22","author":"MS Jeong","year":"2021","unstructured":"Jeong MS, Lee KW, Choi YJ et al (2021) Synergistic antitumor activity of SH003 and docetaxel via EGFR signaling inhibition in non-small cell lung cancer. Int J Mol Sci 22(16):8405. https:\/\/doi.org\/10.3390\/ijms22168405","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10361_CR63","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.3390\/cancers14194568","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Li Q, Huang Z, Li B, Nice EC, Huang C, Wei L, Zou B (2022) Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies. Cancers 14(19):4568. https:\/\/doi.org\/10.3390\/cancers14194568","journal-title":"Cancers"},{"issue":"7","key":"10361_CR64","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1158\/0008-5472.CAN-06-3717","volume":"67","author":"AL Simons","year":"2007","unstructured":"Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR (2007) 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Can Res 67(7):3364\u20133370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3717","journal-title":"Can Res"},{"issue":"1","key":"10361_CR65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s43018-023-00649-1","volume":"5","author":"MV Recouvreux","year":"2024","unstructured":"Recouvreux MV, Grenier SF, Zhang Y, Esparza E, Lambies G, Galapate CM, Maganti S, Duong-Polk K, Bhullar D, Naeem R, Scott DA, Lowy AM, Tiriac H, Commisso C (2024) Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma. Nature cancer 5(1):100\u2013113. https:\/\/doi.org\/10.1038\/s43018-023-00649-1","journal-title":"Nature cancer"},{"issue":"3","key":"10361_CR66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/cancers11030317","volume":"11","author":"T Fan","year":"2019","unstructured":"Fan T, Sun G, Sun X, Zhao L, Zhong R, Peng Y (2019) Tumor energy metabolism and potential of 3-Bromopyruvate as an inhibitor of aerobic glycolysis: implications in tumor treatment. Cancers 11(3):317. https:\/\/doi.org\/10.3390\/cancers11030317","journal-title":"Cancers"},{"issue":"3","key":"10361_CR67","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.clnu.2020.06.028","volume":"40","author":"A Khodabakhshi","year":"2021","unstructured":"Khodabakhshi A, Akbari ME, Mirzaei HR, Seyfried TN, Kalamian M, Davoodi SH (2021) Effects of ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. Clin Nutr 40(3):751\u2013758","journal-title":"Clin Nutr"},{"key":"10361_CR68","doi-asserted-by":"crossref","unstructured":"Zahra, A., Fath, M. A., Opat, E., Mapuskar, K. A., Bhatia, S. K., Ma, D. C., ... & Allen, B. G. (2017). Consuming a ketogenic diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer The University of Iowa experience of two phase clinical trials. Radiation Research. 187(6): 743\u2013754","DOI":"10.1667\/RR14668.1"},{"key":"10361_CR69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2018.00092","volume":"8","author":"A Suraweera","year":"2018","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ (2018) Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol 8:92. https:\/\/doi.org\/10.3389\/fonc.2018.00092","journal-title":"Front Oncol"},{"key":"10361_CR70","doi-asserted-by":"publisher","first-page":"1072651","DOI":"10.3389\/fphar.2022.1072651","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang G, Li Y, Lei D, Xiang J, Ouyang L, Wang Y, Yang J (2022) Recent progress in DNA methyltransferase inhibitors as anticancer agents. Front Pharmacol 13:1072651. https:\/\/doi.org\/10.3389\/fphar.2022.1072651","journal-title":"Front Pharmacol"},{"key":"10361_CR71","doi-asserted-by":"publisher","first-page":"1085391","DOI":"10.3389\/fgene.2022.1085391","volume":"13","author":"L Ren","year":"2023","unstructured":"Ren L, Yang Y, Li W, Yang H, Zhang Y, Ge B, Zhang S, Du G, Wang J (2023) Recent advances in epigenetic anticancer therapeutics and future perspectives. Front Genet 13:1085391. https:\/\/doi.org\/10.3389\/fgene.2022.1085391","journal-title":"Front Genet"},{"issue":"10","key":"10361_CR72","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/jpm13101487","volume":"13","author":"L L\u00f3pez-G\u00f3mez","year":"2023","unstructured":"L\u00f3pez-G\u00f3mez L, Alcorta A, Abalo R (2023) Probiotics and Probiotic-like Agents against chemotherapy-Induced Intestinal Mucositis: A Narrative Review. J Personal Med 13(10):1487. https:\/\/doi.org\/10.3390\/jpm13101487","journal-title":"J Personal Med"},{"issue":"1","key":"10361_CR73","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/ijms23010488","volume":"23","author":"A Sevcikova","year":"2022","unstructured":"Sevcikova A, Izoldova N, Stevurkova V, Kasperova B, Chovanec M, Ciernikova S, Mego M (2022) The impact of the microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. Int J Mol Sci 23(1):488. https:\/\/doi.org\/10.3390\/ijms23010488","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10361_CR74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/hum.2017.209","volume":"29","author":"ZY He","year":"2018","unstructured":"He ZY, Zhang YG, Yang YH, Ma CC, Wang P, Du W, Li L, Xiang R, Song XR, Zhao X, Yao SH, Wei YQ (2018) In vivo ovarian cancer gene therapy using CRISPR-Cas9. Hum Gene Ther 29(2):223\u2013233. https:\/\/doi.org\/10.1089\/hum.2017.209","journal-title":"Hum Gene Ther"},{"issue":"13","key":"10361_CR75","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1039\/D1BM01452H","volume":"10","author":"N Rouatbi","year":"2022","unstructured":"Rouatbi N, McGlynn T, Al-Jamal KT (2022) Pre-clinical non-viral vectors exploited for in vivo CRISPR\/Cas9 gene editing: An overview. Biomaterials Science 10(13):3410\u20133432","journal-title":"Biomaterials Science"},{"issue":"12","key":"10361_CR76","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.ymthe.2019.08.012","volume":"27","author":"L Jubair","year":"2019","unstructured":"Jubair L, Fallaha S, McMillan NAJ (2019) Systemic delivery of CRISPR\/Cas9 targeting HPV oncogenes Is effective at eliminating established tumors. Molecular therapy\u202f: the journal of the American Society of Gene Therapy 27(12):2091\u20132099. https:\/\/doi.org\/10.1016\/j.ymthe.2019.08.012","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"key":"10361_CR77","doi-asserted-by":"crossref","unstructured":"Shimada, H., Matsubara, H., Shiratori, T., Shimizu, T., Miyazaki, S., Okazumi, S., ... & Ochiai, T. (2006). Phase I\/II adenoviral p53 gene therapy for chemoradiation-resistant advanced esophageal squamous cell carcinoma. Cancer Science, 97(6), 554\u2013561.","DOI":"10.1111\/j.1349-7006.2006.00206.x"},{"key":"10361_CR78","doi-asserted-by":"crossref","unstructured":"Tong, A. W., Nemunaitis, J., Su, D., Zhang, Y., Cunningham, C., Senzer, N., ... & Chada, S. (2005). Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7\/IL24): Biologic outcome in advanced cancer patients. Molecular Therapy, 11(1), 160\u2013172.","DOI":"10.1016\/j.ymthe.2004.09.021"},{"key":"10361_CR79","doi-asserted-by":"crossref","unstructured":"Adair, J. E., Johnston, S. K., Mrugala, M. M., Beard, B. C., Guyman, L. A., Baldock, A. L., ... & Kiem, H. P. (2014). Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. The Journal of Clinical Investigation, 124(9), 4082\u20134092.","DOI":"10.1172\/JCI76739"},{"key":"10361_CR80","doi-asserted-by":"crossref","unstructured":"Nasu, Y., Saika, T., Ebara, S., Kusaka, N., Kaku, H., Abarzua, F., ... & Kumon, H. (2007). Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.\u00a0Molecular therapy,\u00a015(4), 834\u2013840.","DOI":"10.1038\/sj.mt.6300096"},{"key":"10361_CR81","doi-asserted-by":"publisher","unstructured":"Kaplan MA, Galkin VN, Romanko YS, et al (2016) Combination photodynamic therapy sarcomas M-1 in combination with chemotherapy. Radiation Risk. https:\/\/doi.org\/10.21870\/0131-3878-2016-25-4-90-99","DOI":"10.21870\/0131-3878-2016-25-4-90-99"},{"key":"10361_CR82","doi-asserted-by":"publisher","unstructured":"Marginter D, T\u00f3th J, Buijs L, Gehlen H (2021) Multimodal therapy of the periorbital equine sarcoid. Pferdeheilkunde. https:\/\/doi.org\/10.21836\/PEM20210308","DOI":"10.21836\/PEM20210308"},{"issue":"6","key":"10361_CR83","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5306\/wjco.v14.i6.215","volume":"14","author":"G Fiorentini","year":"2023","unstructured":"Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C (2023) Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World journal of clinical oncology 14(6):215\u2013226. https:\/\/doi.org\/10.5306\/wjco.v14.i6.215","journal-title":"World journal of clinical oncology"},{"issue":"1","key":"10361_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/ijms23010035","volume":"23","author":"D Salvador","year":"2021","unstructured":"Salvador D, Bastos V, Oliveira H (2021) Hyperthermia enhances Doxorubicin therapeutic efficacy against A375 and MNT-1 Melanoma Cells. Int J Mol Sci 23(1):35. https:\/\/doi.org\/10.3390\/ijms23010035","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10361_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0360-3016(94)90154-6","volume":"28","author":"R Valdagni","year":"1993","unstructured":"Valdagni R, Amichetti M (1993) Report of a long-term follow-up in a randomized trial comparing radiation therapy and radiation plus hyperthermia to metastatic lymph nodes in stage IV head and neck cancer patients. Int J Radiat Oncol 28(1):163\u2013169","journal-title":"Int J Radiat Oncol"},{"key":"10361_CR86","doi-asserted-by":"crossref","unstructured":"Wust, P., Hildebrandt, B., Sreenivasa, G., Rau, B., Gellermann, J., Riess, H., ... & Schlag, P. M. (2002). Hyperthermia in combined treatment of cancer.\u00a0The lancet oncology,\u00a03(8), 487\u2013497.","DOI":"10.1016\/S1470-2045(02)00818-5"},{"key":"10361_CR87","doi-asserted-by":"publisher","first-page":"1702446","DOI":"10.1002\/smll.201702446","volume":"14","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Huang F, Yang Y et al (2018) Paraptosis-inducing nanomedicine overcomes cancer drug resistance for a potent cancer therapy. Small 14:1702446. https:\/\/doi.org\/10.1002\/smll.201702446","journal-title":"Small"},{"key":"10361_CR88","doi-asserted-by":"publisher","unstructured":"Ulldemolins, A., Seras-Franzoso, J., Andrade, F., Rafael, D., Abasolo, I., Gener, P., & Schwartz, S., Jr (2021). Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer drug resistance. (Alhambra, Calif.), 4(1): 44\u201368. https:\/\/doi.org\/10.20517\/cdr.2020.59","DOI":"10.20517\/cdr.2020.59"},{"issue":"37","key":"10361_CR89","doi-asserted-by":"publisher","first-page":"20758","DOI":"10.1039\/c8ra03375g","volume":"8","author":"M Ripoll","year":"2018","unstructured":"Ripoll M, Pierdant M, Neuberg P, Bagnard D, Wagner A, Kichler A, Remy JS (2018) Co-delivery of anti-PLK-1 siRNA and camptothecin by nanometric polydiacetylenic micelles results in a synergistic cell killing. RSC Adv 8(37):20758\u201320763. https:\/\/doi.org\/10.1039\/c8ra03375g","journal-title":"RSC Adv"},{"key":"10361_CR90","doi-asserted-by":"crossref","unstructured":"Zhang, L., Wang, P., Feng, Q., Wang, N., Chen, Z., Huang, Y., ... & Jiang, X. (2017). Lipid nanoparticle-mediated efficient delivery of CRISPR\/Cas9 for tumor therapy. NPG Asia Materials, 9(10), e441-e441.","DOI":"10.1038\/am.2017.185"},{"key":"10361_CR91","unstructured":"National Cancer Institute. (2022, May 31).\u00a0Targeted Therapy to Treat Cancer National Cancer Institute; Cancer.gov. https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies"},{"issue":"Suppl 1","key":"10361_CR92","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10549-005-9036-4","volume":"93","author":"RI Nicholson","year":"2005","unstructured":"Nicholson RI, Johnston SR (2005) Endocrine therapy\u2013current benefits and limitations. Breast Cancer Res Treat 93(Suppl 1):S3-10. https:\/\/doi.org\/10.1007\/s10549-005-9036-4","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10361_CR93","first-page":"514","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL (2017) Cancer immunotherapy, part 3: challenges and future trends. Pharmacy Therapeut 42(8):514","journal-title":"Pharmacy Therapeut"},{"key":"10361_CR94","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2147\/btt.s484068","volume":"18","author":"A Jen\u010da","year":"2024","unstructured":"Jen\u010da A, Mills D, Ghasemi H, Saberian E, Jen\u010da A, Karimi M, Petr\u00e1\u0161ov\u00e1 A, Jen\u010dov\u00e1 J, Velisdeh ZJ, Zare-Zardini H, Ebrahimifar M (2024) Herbal therapies for cancer treatment: a review of phytotherapeutic efficacy. Biologics 18:229\u2013255. https:\/\/doi.org\/10.2147\/btt.s484068","journal-title":"Biologics"},{"key":"10361_CR95","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1097\/00125817-200211001-00011","volume":"4","author":"DS Heo","year":"2002","unstructured":"Heo DS (2002) Progress and limitations in cancer gene therapy. Genet Med 4:S52\u2013S55","journal-title":"Genet Med"},{"issue":"1","key":"10361_CR96","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/21655979.2021.2012907","volume":"13","author":"M Rasool","year":"2022","unstructured":"Rasool M, Malik A, Waquar S, Arooj M, Zahid S, Asif M, Shaheen S, Hussain A, Ullah H, Gan SH (2022) New challenges in the use of nanomedicine in cancer therapy. Bioengineered 13(1):759\u2013773. https:\/\/doi.org\/10.1080\/21655979.2021.2012907","journal-title":"Bioengineered"},{"key":"10361_CR97","unstructured":"Medicine, N. (n.d.).\u00a0Hyperthermia. Northwestern Medicine. https:\/\/www.nm.org\/conditions-and-care-areas\/treatments\/hyperthermia"},{"issue":"7","key":"10361_CR98","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1136\/gutjnl-2021-326264","volume":"71","author":"NL Ting","year":"2022","unstructured":"Ting NL, Lau HC, Yu J (2022) Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 71(7):1412\u20131425. https:\/\/doi.org\/10.1136\/gutjnl-2021-326264","journal-title":"Gut"},{"issue":"1","key":"10361_CR99","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ctrv.2013.05.009","volume":"40","author":"P Bojang Jr","year":"2014","unstructured":"Bojang P Jr, Ramos KS (2014) The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev 40(1):153\u2013169. https:\/\/doi.org\/10.1016\/j.ctrv.2013.05.009","journal-title":"Cancer Treat Rev"},{"key":"10361_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113854","volume":"176","author":"N Batis","year":"2021","unstructured":"Batis N, Brooks JM, Payne K, Sharma N, Nankivell P, Mehanna H (2021) Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. Adv Drug Deliv Rev 176:113854. https:\/\/doi.org\/10.1016\/j.addr.2021.113854","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10361_CR101","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/biom13020194","volume":"13","author":"AK Wani","year":"2023","unstructured":"Wani AK, Akhtar N, Mir TUG, Singh R, Jha PK, Mallik SK, Sinha S, Tripathi SK, Jain A, Jha A, Devkota HP, Prakash A (2023) Targeting apoptotic pathway of cancer cells with phytochemicals and plant-based nanomaterials. Biomolecules 13(2):194. https:\/\/doi.org\/10.3390\/biom13020194","journal-title":"Biomolecules"},{"key":"10361_CR102","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","volume":"13","author":"A Bolomsky","year":"2020","unstructured":"Bolomsky A, Vogler M, K\u00f6se MC et al (2020) MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J Hematol Oncol 13:173. https:\/\/doi.org\/10.1186\/s13045-020-01007-9","journal-title":"J Hematol Oncol"},{"key":"10361_CR103","doi-asserted-by":"publisher","unstructured":"Pulumati, A., Pulumati, A., Dwarakanath, B. S., Verma, A., & Papineni, R. V. L. (2023). Technological advancements in cancer diagnostics Improvements and limitations. Cancer reports (Hoboken, N.J.), 6(2), e1764. https:\/\/doi.org\/10.1002\/cnr2.1764","DOI":"10.1002\/cnr2.1764"},{"issue":"9","key":"10361_CR104","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ph16091283","volume":"16","author":"G Biala","year":"2023","unstructured":"Biala G, Kedzierska E, Kruk-Slomka M, Orzelska-Gorka J, Hmaidan S, Skrok A, Kaminski J, Havrankova E, Nadaska D, Malik I (2023) Research in the field of drug design and development. Pharmaceuticals (Basel, Switzerland) 16(9):1283. https:\/\/doi.org\/10.3390\/ph16091283","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"3\u20134","key":"10361_CR105","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1142\/S2339547818300020","volume":"6","author":"P Krzyszczyk","year":"2018","unstructured":"Krzyszczyk P, Acevedo A, Davidoff EJ, Timmins LM, Marrero-Berrios I, Patel M, White C, Lowe C, Sherba JJ, Hartmanshenn C, O\u2019Neill KM, Balter ML, Fritz ZR, Androulakis IP, Schloss RS, Yarmush ML (2018) The growing role of precision and personalized medicine for cancer treatment. Technology 6(3\u20134):79\u2013100. https:\/\/doi.org\/10.1142\/S2339547818300020","journal-title":"Technology"},{"key":"10361_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11936-018-0641-z","volume":"20","author":"LL Tan","year":"2018","unstructured":"Tan LL, Lyon AR (2018) Role of biomarkers in prediction of cardiotoxicity during cancer treatment. Curr Treat Options Cardiovasc Med 20:1\u201314","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10361_CR107","doi-asserted-by":"crossref","unstructured":"Colomer, R., Miranda, J., Romero-Laorden, N., Hornedo, J., Gonz\u00e1lez-Cortijo, L., Mouron, S., & Quintela-Fandino, M. (2023). Usefulness and real-world outcomes of next generation sequencing testing in patients with cancer: an observational study on the impact of selection based on clinical judgement. eClinicalMedicine 60: 102029.","DOI":"10.1016\/j.eclinm.2023.102029"},{"issue":"7","key":"10361_CR108","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41416-024-02634-6","volume":"130","author":"AE Yuzhalin","year":"2024","unstructured":"Yuzhalin AE (2024) Redefining cancer research for therapeutic breakthroughs. Br J Cancer 130(7):1078\u20131082. https:\/\/doi.org\/10.1038\/s41416-024-02634-6","journal-title":"Br J Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10361-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10361-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:36:17Z","timestamp":1766853377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10361-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10361"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10361-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"239"}}